| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cea139ad438b9ce7d33159d45b154c6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc62792656aa2e858252e97e5ffaca79 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24362
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24371
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-183 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate |
2014-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac3b506a1cc35ac262b3d3ff7aaa5e42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56200581ffae87f5710997a80dd2e90a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b78d6b2da509a32498df24e0cd523f57 |
| publicationDate |
2015-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015250866-A1 |
| titleOfInvention |
Live Attenuated Antigenically Marked Classical Swine Fever Vaccine |
| abstract |
Controlling Classical Swine Fever Virus (CSFV) involves either prophylactic vaccination or non-vaccination and elimination of infected herds depending on the epidemiological situation. Marker vaccines allowing distinction between naturally infected from vaccinated swine could complement “stamping out” measures. Previously, we reported the development of FlagT4v, a double antigenic marker live attenuated CSFV strain. FlagT4v was later shown as not to be completely stable in terms of its attenuation when assessed in a reversion to virulence protocol. We have developed a modified version of the FlagT4v where changes in the codon usage of genomic areas encoding for Flag and T4 were introduced to rectify the reversion to the virulent genotype. The new virus, FlagT4-mFT-Gv, possesses the same amino acid sequence as FlagT4v except for one substitution, Asparagine is replaced by Glycine at position 852 of the CSFV polypeptide. FlagT4-mFT-Gv protected swine against challenge with Brescia virulent virus at 21 days post vaccination. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109952310-A |
| priorityDate |
2014-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |